Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

United States Business Intelligence Software Market Analysis 2025-2033 by Technology, Deployment, Enterprise, End User, States and Competitive Landscape

View original at globenewswire.com
United States Business Intelligence Software Market Analysis 2025-2033 by Technology, Deployment, Enterprise, End User, States and Competitive Landscape Dublin, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The United States Business Intelligence Software Market is expected to grow from US$ 11.35 Billion in 2024 to US$ 27.49 Billion by 2033

    80% confidence
  • Qlik is on a mission to enable today's businesses to turn trust data into something actionable, access it, analyze it and act on it

    80% confidence
  • Cloud BI has the potential to lead the U.S. BI market in the future years due to increasing popularity of subscription-based models and superior security protocols

    80% confidence
  • The U.S. BI software market will demonstrate a Compound Annual Growth Rate of 10.33% during 2025 to 2033

    80% confidence
  • High implementation and maintenance costs remain a challenge in the U.S. BI market, particularly for small and mid-size businesses

    80% confidence
  • More than 80% of companies will move to the cloud as of 2024

    80% confidence
  • The drivers of BI market growth are rising data-driven decision-making, improving analytics, and growing demands for data visualization and reporting tools from companies across industries

    80% confidence
  • Data security is a major issue in BI software adoption, especially for industries like healthcare, banking, and government dealing with sensitive data

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com